Olaparib and ovarian cancer-overall survival outcomes

Affiliations

Comment

Sean Kehoe. Lancet Oncol. 2016 Nov.

. 2016 Nov;17(11):1474-1475.

doi: 10.1016/S1470-2045(16)30433-8.

¹ Institute of Cancer and Genomics, University of Birmingham, Birmingham B15 2TT, UK. Electronic address: s.t.kehoe@bham.ac.uk.

No abstract available

Comment on

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Ledermann JA, et al. Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9. Lancet Oncol. 2016. PMID: 27617661 Clinical Trial.